Preservation of kidney function irrelevant of total kidney volume growth rate with tolvaptan treatment in patients with autosomal dominant polycystic kidney disease

ConclusionTolvaptan was effective in slowing eGFR decline, regardless of TKV response, over 3  years in patients with ADPKD in Japan. Treatment with tolvaptan may have beneficial effects on slowing of renal function decline even in patients who have not experienced a reduction in the rate of TKV growth by treatment with tolvaptan.
Source: Clinical and Experimental Nephrology - Category: Urology & Nephrology Source Type: research